INNOVATION | FOOD TECHNOLOGY

Precision fermentation has spent much of the past decade proving what biotechnology can make. The next phase is about proving what it can manufacture economically.

Key Takeaways

• Scale is becoming the critical test. Producing an ingredient in a lab does not guarantee commercially viable manufacturing.
• Existing fermentation infrastructure is becoming strategically valuable. Partnerships with established processors can cut capital costs and speed market entry.
• Downstream processing matters as much as fermentation yield. Recovery, purification and stabilization strongly influence economics.
• High-value ingredients may scale before commodities. Specialty proteins, enzymes and bioactives can tolerate higher production costs.
• Consumer and regulatory acceptance remain essential. Manufacturing success alone will not create a viable market.

From Breakthrough to Industrial Execution

Using engineered microorganisms as production platforms, companies can produce proteins, enzymes, fats, flavours and bioactive compounds traditionally sourced from animals, plants or other supply chains. The science has advanced rapidly; commercialization has been harder.

A February 2026 paper in Trends in Food Science & Technology argues technical feasibility alone doesn’t establish whether precision fermentation is economically or environmentally competitive: feedstocks, electricity use, waste management and process design all shape cost and environmental performance.

That challenge extends downstream. A 2025 review in Current Opinion in Food Science identified downstream processing, separating, purifying and stabilizing the target molecule, as a critical bottleneck. An August 2026 review in Current Opinion in Biotechnology found only a limited number of precision-fermentation ingredients have reached commercial markets, flagging fermentation-specific techno-economic analysis as a key gap.

Industry Responds With Manufacturing Partnerships

One sign of this shift is the growing relationship between biotechnology developers and established industrial manufacturers.

In July 2026, ADM and The EVERY Company announced plans to produce EVERY’s OvoPro egg-white protein at commercial scale at ADM’s Clinton, Iowa facility, giving the ingredient its first US manufacturing base rather than requiring EVERY to build new capacity.

That same month, Novonesis partnered with TurtleTree to scale, manufacture and commercialize TurtleTree’s precision-fermented lactoferrin, LF+, pairing a biotech developer’s platform with an established biosolutions company’s manufacturing and commercial reach.

New infrastructure is also emerging to bridge lab and industrial scale. In the Netherlands, GEA is supplying an open-access precision and biomass fermentation upscaling line at the NIZO Food Innovation Campus in Ede, designed to let companies validate processes under food-grade conditions before commercial production.

The pattern is significant: precision fermentation is increasingly an infrastructure and manufacturing story, not simply a biotechnology one.

Where the Opportunity May Be Strongest

Commercial economics could shape which ingredients scale first. Rather than competing immediately with inexpensive commodity proteins and fats, precision fermentation may have stronger near-term opportunities where functionality, scarcity or supply-chain resilience justify higher costs: specialty dairy proteins like lactoferrin, functional egg proteins, enzymes, flavour compounds, bioactives and specialty lipids. Despite tighter food-tech investment overall, companies solving specific supply-chain and ingredient-performance problems continue attracting partnerships and capital.

Consumer and Regulatory Readiness

Manufacturing economics won’t be the only test. An August 2026 review in Trends in Food Science & Technology found consumer understanding of precision fermentation remains limited, with acceptance varying by product and context. The FAO’s 2025 assessment likewise flagged food-safety considerations throughout production and the need for appropriate regulatory oversight as more products reach global markets.

Why It Matters

The industry’s first phase asked whether microorganisms could be engineered to produce valuable food ingredients. Increasingly, yes. The harder question now is whether those ingredients can be produced reliably, safely and economically at hundreds of thousands or millions of kilograms rather than lab quantities.

That shifts competitive advantage toward companies combining biotechnology with process engineering, fermentation capacity, downstream processing, regulatory execution and disciplined capital investment. Precision fermentation has largely shown what the science can do. The next frontier is proving what industrial manufacturing can deliver.

---

Sources

1. David, L.H., Juliano, P. & Ridoutt, B.G. The role of techno-economic and life cycle assessment in guiding precision fermentation towards sustainable food production. Trends in Food Science & Technology, 168, 105488, 2026.
2. Cho, S. et al. Precision fermentation for producing food ingredients. Current Opinion in Food Science, 61, 101242, 2025.
3. Current Opinion in Biotechnology. Minimum viable products in precision fermentation: defining translational milestones for food biotechnology. 100, 103515, August 2026.
4. Trends in Food Science & Technology. Sensory evaluation and consumer perception of precision fermentation-derived foods. 174, 105791, August 2026.
5. ADM and The EVERY Company. Joint announcement. July 14, 2026.
6. Novonesis and TurtleTree. Joint announcement. July 2026.
7. GEA and NIZO Food Innovation Campus. Joint announcement. January 13, 2026.
8. FAO. Precision fermentation food-safety assessment. 2025.